1355335-99-7

Upstream product

• 40499-83-0 pyrrolidin-3-ol 
• 591-18-4 1-Bromo-3-iodobenzene 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 1355336-00-3 1-(3-bromophenyl)-3-(tert-butyldimethylsilyloxy)pyrrolidine 
• 1355335-51-1 1-(3-(4-(2-(4-methylpyrimidin-2-ylamino)thiazol-4-yl)-1H-pyrazol-3-yl)phenyl)pyrrolidin-3-ol 
• 1355336-02-5 4-(3-(3-(3-(tert-butyldimethylsilyloxy)pyrrolidin-1-yl)phenyl)-1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-N-(4-methylpyrimidin-2-yl)thiazol-2-amine 
• 1355336-01-4 3-(tert-butyldimethylsilyloxy)-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine 

Relevant academic research and scientific papers

OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1

The present technology is directed to compounds of formula (I), compositions thereof, and methods related to inhibition of ASKI. In particular, the present compounds and compositions may be used to treat ASKl-mediated disorders and conditions, including,

NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (1), wherein M, A and B are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.